Diagenode

H3K4 acetylation, H3K9 acetylation and H3K27 methylation in breast tumor molecular subtypes


Judes G et al.

AIM:

Here, we investigated how the St Gallen breast molecular subtypes displayed distinct histone H3 profiles.

PATIENTS & METHODS:

192 breast tumors divided into five St Gallen molecular subtypes (luminal A, luminal B HER2-, luminal B HER2+, HER2+ and basal-like) were evaluated for their histone H3 modifications on gene promoters.

RESULTS:

ANOVA analysis allowed to identify specific H3 signatures according to three groups of genes: hormonal receptor genes (ERS1, ERS2, PGR), genes modifying histones (EZH2, P300, SRC3) and tumor suppressor gene (BRCA1). A similar profile inside high-risk cancers (luminal B [HER2+], HER2+ and basal-like) compared with low-risk cancers including luminal A and luminal B (HER2-) were demonstrated.

CONCLUSION:

The H3 modifications might contribute to clarify the differences between breast cancer subtypes.

Tags
Antibody
IP-Star Compact

Share this article

Published
July, 2016

Source

Products used in this publication

  • some alt
    B03000002
    IP-Star® Compact Automated System
  • Antibody ChIP-seq grade icon
    C15410039-50
    EZH2 polyclonal antibody
  • Antibody ChIP-seq grade icon
    C15410069
    H3K27me3 polyclonal antibody
  • Antibody ChIP icon
    C15410165
    H3K4ac polyclonal antibody - replaced by the re...
  • Antibody ChIP-seq grade icon
    C15410004
    H3K9ac polyclonal antibody - Classic
  • RFX5-polyclonal-antibody-diagenode
    C15410206
    Rabbit IgG

Events

 See all events

News

 See all news


The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.



  ABOUT SSL CERTIFICATES

       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics